Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Clin Cancer Res. 2013 Aug 5;19(21):10.1158/1078-0432.CCR-13-0850. doi: 10.1158/1078-0432.CCR-13-0850

Figure 4. Significantly enhanced antitumor efficacy following treatment of RD xenografts with AZD8055, but not NVP-BEZ235, in combination with AZD6244.

Figure 4

A. and B. Head-to-head therapeutic study of RD xenografts treated with AZD6244 and either AZD8055 or NVP-BEZ235 respectively at the indicated doses alone, and in combination. Tumor volumes are expressed as a % volume of each tumor on day 0. Final tumor weights (g) show significantly increased efficacy of the combination AZD8055/AZD6244 compared with AZD6244 alone (**p=0.015) or AZD8055 alone (*p=0.038) and no significant difference in efficacy of the combination NVP-BEZ235/ AZD6244 compared with AZD6244 alone (p=0.13) or BEZ235 alone (p=0.82) (Mann Whitney t test). C. Plasma AZD6244 concentrations 3hrs following the final dose in mice treated with AZD6244 alone or in combination with AZD8055 or NVP-BEZ235 and plasma AZD8055 and NVP-BEZ235 concentrations from the same mice as above. D. Tumor PD biomarkers pERK: phospho(T/Y:202/204:185/187)ERK/total ERK1/2, pAKT: phospho(Ser473)AKT/total AKT and pS6: phospho(240/244)S6/total S6, as determined by MSD immunoassay.

HHS Vulnerability Disclosure